Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2014

View Archived Issues

Heptares achieves research milestone in antibody collaboration with MedImmune

Johnson & Johnson reports regulatory news of fourth quarter 2013

Identification of RNA transcription enzyme repressors as novel anticancer drugs

Dendrimer-enhanced docetaxel clinical trial to begin in patients with solid tumors

Amgen reports topline data from phase III GAUSS-2 trial

Kancera to develop a vaccine against ROR to prevent cancer relapse

BioLineRx receives FDA orphan drug designation for stem cell mobilization therapy

California Stem Cell submits phase II trial protocol to FDA for Ovapuldencel-T

Pfizer reports topline results from phase III study of ALO-02

CytRx begins phase II trial of aldoxorubicin for AIDS-related Kaposi's sarcoma

DiaGenic reports final results from exploratory study of blood test for Alzheimer's disease

MDxHealth and Teva Pharmaceuticals sign agreement to commercialize two cancer tests in Israel

Japanese researchers present novel GSK-3 inhibitors for cancer

Roche discloses new agents for HCV infection

FDA grants orphan drug status to Aeolus' drug candidate for treatment of acute radiation syndrome

Novel fatty acid synthase inhibitors patented by GlaxoSmithKline

Novel PCSK9 inhibitors designed by Cadila Healthcare for dyslipidemia

Isis Innovation divulges new RNA polymerase inhibitors for infections

Novartis to request re-examination of E.U. filing for serelaxin

EMA committee recommends approval of Xolair in new indication

Endo and BioDelivery report results from phase III trial of BEMA buprenorphine in chronic pain

Valeant completes acquisition of Solta Medical

KIF20A-derived peptide plus gemcitabine evaluated in pancreatic cancer trial

Previously identified RIP1 kinase inhibitor potentially useful for necroptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026